Copertina

Evidence Generation for Drugs and Biological Products isn't Magic or Myth

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	John Concato, Leonard Sacks, Peter Stein, Jacqueline Corrigan‐Curay
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Clinical Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Real‐World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020–2022
di: Gabriel K. Innes, et al.
Pubblicazione: (2025)

US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience
di: Kimberly A. Smith, et al.
Pubblicazione: (2025)

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost
di: Vaishali Sahasrabudhe, et al.
Pubblicazione: (2025)

Identifying Drug–Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects
di: Elpida Kontsioti, et al.
Pubblicazione: (2024)

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs
di: Darshak Gadara, et al.
Pubblicazione: (2026)

Thinking Three‐Dimensionally: A Self‐ and Externally‐Controlled Approach to Screening for Drug–Drug–Drug Interactions Among High‐Risk Populations
di: Emily K. Acton, et al.
Pubblicazione: (2024)

Assessment of Dosing Strategies for Pediatric Drug Products
di: Zachary L. Taylor, et al.
Pubblicazione: (2024)

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment
di: Sébastien Taillemite, et al.
Pubblicazione: (2026)

Assessment of Efficacy Evidence for Approvals of Novel Drugs in China Between 2018 and 2022
di: Yang Xu, et al.
Pubblicazione: (2024)

Balancing Reassurance and Vigilance: Real‐World Evidence in Post‐Marketing Drug Safety
di: Yow‐Ming C. Wang, et al.
Pubblicazione: (2026)

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients
di: Anita Iacono, et al.
Pubblicazione: (2026)

Use of FDA Expedited Programs and Development Timelines for New Molecular Entity Drug and New Biologic Approvals by Sponsor Experience
di: Kanhai S. Amin, et al.
Pubblicazione: (2025)

Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women
di: Norah Mwebaza, et al.
Pubblicazione: (2024)

Use of Real‐World Data and Real‐World Evidence in Rare Disease Drug Development: A Statistical Perspective
di: Jie Chen, et al.
Pubblicazione: (2025)

New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans
di: Arne Gessner, et al.
Pubblicazione: (2024)

Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes
di: Roberto Viviani, et al.
Pubblicazione: (2024)

High Virologic Suppression and Favorable Profiles of Two‐Drug Antiretroviral Regimens in Africa: A Systematic Review of Current Evidence
di: Paul Achile Akpa, et al.
Pubblicazione: (2025)

Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio
di: Aiden‐Hung P. Nguyen, et al.
Pubblicazione: (2026)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails
di: Niels A. D. Guchelaar, et al.
Pubblicazione: (2024)

Biomarker Utilization for Regulatory Decision Making: A Landscape Analysis of Neurological Drug Products Approved by FDA (2008–2024)
di: Dahee Jung, et al.
Pubblicazione: (2025)

Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability
di: Sarah K. Emond, et al.
Pubblicazione: (2025)

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development
di: Simeon Rüdesheim, et al.
Pubblicazione: (2025)

Drug Interactions Brewing
di: Matthijs W. van Hoogdalem, et al.
Pubblicazione: (2025)

Gut Microbiota in Patients with Tuberculosis Associated with Different Drug Exposures of Antituberculosis Drugs
di: Yue Zhu, et al.
Pubblicazione: (2025)

Clinical Evaluation of Drug–Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent
di: Chi‐Chi Peng, et al.
Pubblicazione: (2025)

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
di: Amitava Mitra, et al.
Pubblicazione: (2024)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
di: Mark J. Ratain
Pubblicazione: (2024)

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
di: Cornelius Cilliers, et al.
Pubblicazione: (2024)

The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report
di: Anna M. G. Pasmooij, et al.
Pubblicazione: (2024)

Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years
di: Sachiko Mita, et al.
Pubblicazione: (2025)

Chat GPT and the Challenges to Detect Potential Drug–Drug Interactions Related to QT Prolongation
di: Emanuel Raschi, et al.
Pubblicazione: (2025)

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals
di: George S. Q. Tan, et al.
Pubblicazione: (2025)

Sex and the Kidney Drug‐Metabolizing Enzymes and Transporters: Are Preclinical Drug Disposition Data Translatable to Humans?
di: Aarzoo Thakur, et al.
Pubblicazione: (2024)

Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers
di: Kenza Abouir, et al.
Pubblicazione: (2024)

Clinical Evidence 2030
di: Peter Arlett, et al.
Pubblicazione: (2025)

Drug Loss in Japan: A Comparative Analysis with Europe for New Drugs Developed by Emerging Biopharma Companies
di: Mihoko Kobayashi, et al.
Pubblicazione: (2025)

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development
di: Tanja S. Zabka, et al.
Pubblicazione: (2025)

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions
di: Kunal S. Taskar, et al.
Pubblicazione: (2025)

The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway
di: Rajanikanth Madabushi, et al.
Pubblicazione: (2024)

Response to Letters Regarding “Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors”
di: Léonard Laurent, et al.
Pubblicazione: (2025)